Clinical Trial Update: CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial of CD19-CAR immunotherapy for childhood acute lymphoblastic leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• CD19-CAR immunotherapy

Snippet

Sponsor: University College, London | Conditions: Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: TERMINATED